Conditional Survival and Long-Term Efficacy With Nivolumab Plus Ipilimumab vs Sunitinib in Advanced RCC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma
Cancer 2022 Apr 05;[EPub Ahead of Print], RJ Motzer, DF McDermott, B Escudier, M Burotto, TK Choueiri, HJ Hammers, P Barthélémy, ER Plimack, C Porta, S George, T Powles, F Donskov, H Gurney, CK Kollmannsberger, MO Grimm, C Barrios, Y Tomita, D Castellano, V Grünwald, BI Rini, MB McHenry, CW Lee, J McCarthy, F Ejzykowicz, NM TannirFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.